EA011261B1 - Гликопротеин клеточной поверхности - Google Patents

Info

Publication number

EA011261B1

EA011261B1 EA200700425A EA200700425A EA011261B1 EA 011261 B1 EA011261 B1 EA 011261B1 EA 200700425 A EA200700425 A EA 200700425A EA 200700425 A EA200700425 A EA 200700425A EA 011261 B1 EA011261 B1 EA 011261B1

Authority

EA

Eurasian Patent Office

Prior art keywords

polypeptide

nucleic acid

disease

acid molecule

compound

Prior art date

2004-08-11

Links

• Espacenet
• Global Dossier
• Discuss

• 102000012750 Membrane Glycoproteins Human genes 0.000 title claims abstract description 33
• 108010090054 Membrane Glycoproteins Proteins 0.000 title claims abstract description 33
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 191
• 150000007523 nucleic acids Chemical group 0.000 claims abstract description 159
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 113
• 201000010099 disease Diseases 0.000 claims abstract description 93
• 238000011282 treatment Methods 0.000 claims abstract description 73
• 238000003745 diagnosis Methods 0.000 claims abstract description 13
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 517
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 498
• 229920001184 polypeptide Polymers 0.000 claims description 493
• 238000000034 method Methods 0.000 claims description 225
• 210000004027 cell Anatomy 0.000 claims description 218
• 102000039446 nucleic acids Human genes 0.000 claims description 151
• 108020004707 nucleic acids Proteins 0.000 claims description 151
• 150000001875 compounds Chemical class 0.000 claims description 133
• 230000014509 gene expression Effects 0.000 claims description 106
• 239000012634 fragment Substances 0.000 claims description 95
• 238000009739 binding Methods 0.000 claims description 82
• 230000000694 effects Effects 0.000 claims description 82
• 230000027455 binding Effects 0.000 claims description 81
• 241000282414 Homo sapiens Species 0.000 claims description 80
• 239000003446 ligand Substances 0.000 claims description 67
• 239000000203 mixture Substances 0.000 claims description 61
• 239000013598 vector Substances 0.000 claims description 59
• 206010028980 Neoplasm Diseases 0.000 claims description 58
• 239000000523 sample Substances 0.000 claims description 54
• 239000000427 antigen Substances 0.000 claims description 52
• 108091007433 antigens Proteins 0.000 claims description 52
• 102000036639 antigens Human genes 0.000 claims description 52
• 239000000556 agonist Substances 0.000 claims description 49
• 239000005557 antagonist Substances 0.000 claims description 33
• 201000011510 cancer Diseases 0.000 claims description 33
• 238000004519 manufacturing process Methods 0.000 claims description 28
• 238000012216 screening Methods 0.000 claims description 27
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
• 238000001514 detection method Methods 0.000 claims description 26
• 241001465754 Metazoa Species 0.000 claims description 25
• 239000008194 pharmaceutical composition Substances 0.000 claims description 25
• 239000003814 drug Substances 0.000 claims description 23
• 230000035772 mutation Effects 0.000 claims description 23
• 230000015572 biosynthetic process Effects 0.000 claims description 20
• 239000003153 chemical reaction reagent Substances 0.000 claims description 20
• 208000035475 disorder Diseases 0.000 claims description 20
• 102000004190 Enzymes Human genes 0.000 claims description 19
• 108090000790 Enzymes Proteins 0.000 claims description 19
• 108020003175 receptors Proteins 0.000 claims description 19
• 230000001225 therapeutic effect Effects 0.000 claims description 19
• 229960005486 vaccine Drugs 0.000 claims description 16
• 239000000758 substrate Substances 0.000 claims description 15
• 102000003886 Glycoproteins Human genes 0.000 claims description 12
• 108090000288 Glycoproteins Proteins 0.000 claims description 12
• 230000004071 biological effect Effects 0.000 claims description 12
• 239000003795 chemical substances by application Substances 0.000 claims description 12
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
• 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 9
• 239000002853 nucleic acid probe Substances 0.000 claims description 9
• 239000012472 biological sample Substances 0.000 claims description 8
• 239000013068 control sample Substances 0.000 claims description 8
• 230000008506 pathogenesis Effects 0.000 claims description 8
• 230000009261 transgenic effect Effects 0.000 claims description 8
• 206010061218 Inflammation Diseases 0.000 claims description 7
• 208000029742 colonic neoplasm Diseases 0.000 claims description 7
• 230000004054 inflammatory process Effects 0.000 claims description 7
• 230000001413 cellular effect Effects 0.000 claims description 6
• 208000016222 Pancreatic disease Diseases 0.000 claims description 4
• 230000008859 change Effects 0.000 claims description 4
• 230000002950 deficient Effects 0.000 claims description 4
• 229940000406 drug candidate Drugs 0.000 claims description 4
• 206010009944 Colon cancer Diseases 0.000 claims description 3
• 230000007062 hydrolysis Effects 0.000 claims description 3
• 238000006460 hydrolysis reaction Methods 0.000 claims description 3
• 230000001939 inductive effect Effects 0.000 claims description 3
• 230000000527 lymphocytic effect Effects 0.000 claims description 3
• 238000012544 monitoring process Methods 0.000 claims description 3
• 208000024691 pancreas disease Diseases 0.000 claims description 3
• 239000003433 contraceptive agent Substances 0.000 claims 2
• 230000002254 contraceptive effect Effects 0.000 claims 2
• 230000004720 fertilization Effects 0.000 claims 1
• 238000000338 in vitro Methods 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 abstract description 91
• 230000002265 prevention Effects 0.000 abstract description 3
• 235000018102 proteins Nutrition 0.000 description 86
• 108020004414 DNA Proteins 0.000 description 70
• 210000001519 tissue Anatomy 0.000 description 53
• 235000001014 amino acid Nutrition 0.000 description 44
• 150000001413 amino acids Chemical class 0.000 description 41
• 238000002360 preparation method Methods 0.000 description 36
• 239000000047 product Substances 0.000 description 32
• 238000012360 testing method Methods 0.000 description 31
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
• 238000004458 analytical method Methods 0.000 description 30
• 239000002299 complementary DNA Substances 0.000 description 28
• 239000013612 plasmid Substances 0.000 description 28
• 239000000872 buffer Substances 0.000 description 27
• 238000006243 chemical reaction Methods 0.000 description 25
• 210000004379 membrane Anatomy 0.000 description 25
• 239000012528 membrane Substances 0.000 description 25
• 238000000746 purification Methods 0.000 description 24
• 230000006870 function Effects 0.000 description 23
• 230000001105 regulatory effect Effects 0.000 description 23
• 239000007787 solid Substances 0.000 description 21
• 108060003951 Immunoglobulin Proteins 0.000 description 20
• 238000010367 cloning Methods 0.000 description 20
• 102000018358 immunoglobulin Human genes 0.000 description 20
• 201000001441 melanoma Diseases 0.000 description 20
• 230000004048 modification Effects 0.000 description 20
• 238000012986 modification Methods 0.000 description 20
• 238000009396 hybridization Methods 0.000 description 19
• 229940088598 enzyme Drugs 0.000 description 18
• 239000002773 nucleotide Substances 0.000 description 18
• 125000003729 nucleotide group Chemical group 0.000 description 18
• 102000005962 receptors Human genes 0.000 description 18
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 17
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 17
• 238000003556 assay Methods 0.000 description 16
• 210000000170 cell membrane Anatomy 0.000 description 16
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
• 108090000695 Cytokines Proteins 0.000 description 15
• 102000004127 Cytokines Human genes 0.000 description 15
• 125000000539 amino acid group Chemical group 0.000 description 15
• 230000000295 complement effect Effects 0.000 description 15
• 108020004999 messenger RNA Proteins 0.000 description 15
• 230000000890 antigenic effect Effects 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 108020001507 fusion proteins Proteins 0.000 description 14
• 102000037865 fusion proteins Human genes 0.000 description 14
• 239000002609 medium Substances 0.000 description 14
• 238000012163 sequencing technique Methods 0.000 description 14
• 239000000243 solution Substances 0.000 description 14
• 108091034117 Oligonucleotide Proteins 0.000 description 13
• 238000005755 formation reaction Methods 0.000 description 13
• 239000011541 reaction mixture Substances 0.000 description 13
• 241000196324 Embryophyta Species 0.000 description 12
• 241000124008 Mammalia Species 0.000 description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
• 208000020816 lung neoplasm Diseases 0.000 description 12
• 238000006467 substitution reaction Methods 0.000 description 12
• 108091026890 Coding region Proteins 0.000 description 11
• 230000004913 activation Effects 0.000 description 11
• 230000003321 amplification Effects 0.000 description 11
• 208000015181 infectious disease Diseases 0.000 description 11
• 238000003199 nucleic acid amplification method Methods 0.000 description 11
• 230000001575 pathological effect Effects 0.000 description 11
• 241000894007 species Species 0.000 description 11
• 238000010561 standard procedure Methods 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 238000004113 cell culture Methods 0.000 description 10
• YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 10
• 238000001415 gene therapy Methods 0.000 description 10
• 238000006206 glycosylation reaction Methods 0.000 description 10
• 208000027866 inflammatory disease Diseases 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 210000004072 lung Anatomy 0.000 description 10
• 238000003786 synthesis reaction Methods 0.000 description 10
• 208000031886 HIV Infections Diseases 0.000 description 9
• 241000699666 Mus <mouse, genus> Species 0.000 description 9
• 108010076504 Protein Sorting Signals Proteins 0.000 description 9
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
• 230000000692 anti-sense effect Effects 0.000 description 9
• 239000003937 drug carrier Substances 0.000 description 9
• 238000004520 electroporation Methods 0.000 description 9
• 238000005516 engineering process Methods 0.000 description 9
• 239000013604 expression vector Substances 0.000 description 9
• 208000037841 lung tumor Diseases 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 230000001404 mediated effect Effects 0.000 description 9
• 230000004044 response Effects 0.000 description 9
• 230000002441 reversible effect Effects 0.000 description 9
• 230000028327 secretion Effects 0.000 description 9
• 239000006228 supernatant Substances 0.000 description 9
• -1 4-difluoroproline Chemical compound 0.000 description 8
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 8
• 230000002068 genetic effect Effects 0.000 description 8
• 230000013595 glycosylation Effects 0.000 description 8
• 230000002163 immunogen Effects 0.000 description 8
• 239000003112 inhibitor Substances 0.000 description 8
• 210000004962 mammalian cell Anatomy 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
• 210000002966 serum Anatomy 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• 208000023275 Autoimmune disease Diseases 0.000 description 7
• 206010006187 Breast cancer Diseases 0.000 description 7
• 208000026310 Breast neoplasm Diseases 0.000 description 7
• 108090000994 Catalytic RNA Proteins 0.000 description 7
• 102000053642 Catalytic RNA Human genes 0.000 description 7
• 206010025323 Lymphomas Diseases 0.000 description 7
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 7
• 208000006265 Renal cell carcinoma Diseases 0.000 description 7
• 230000002159 abnormal effect Effects 0.000 description 7
• 238000010171 animal model Methods 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 239000000499 gel Substances 0.000 description 7
• 210000004408 hybridoma Anatomy 0.000 description 7
• 239000012535 impurity Substances 0.000 description 7
• 230000003834 intracellular effect Effects 0.000 description 7
• 238000002955 isolation Methods 0.000 description 7
• 208000032839 leukemia Diseases 0.000 description 7
• 210000000265 leukocyte Anatomy 0.000 description 7
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
• 239000000816 peptidomimetic Substances 0.000 description 7
• 108091033319 polynucleotide Proteins 0.000 description 7
• 102000040430 polynucleotide Human genes 0.000 description 7
• 239000002157 polynucleotide Substances 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 238000003127 radioimmunoassay Methods 0.000 description 7
• 108091092562 ribozyme Proteins 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 238000013518 transcription Methods 0.000 description 7
• 238000013519 translation Methods 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• 241000283973 Oryctolagus cuniculus Species 0.000 description 6
• 239000004698 Polyethylene Substances 0.000 description 6
• 102000006382 Ribonucleases Human genes 0.000 description 6
• 108010083644 Ribonucleases Proteins 0.000 description 6
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
• 241000700605 Viruses Species 0.000 description 6
• 150000003862 amino acid derivatives Chemical class 0.000 description 6
• 230000006907 apoptotic process Effects 0.000 description 6
• 230000000903 blocking effect Effects 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
• 238000004587 chromatography analysis Methods 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 231100000673 dose–response relationship Toxicity 0.000 description 6
• 235000011187 glycerol Nutrition 0.000 description 6
• 238000003780 insertion Methods 0.000 description 6
• 230000037431 insertion Effects 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 230000004807 localization Effects 0.000 description 6
• 201000005202 lung cancer Diseases 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 238000012545 processing Methods 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 239000008223 sterile water Substances 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 238000001890 transfection Methods 0.000 description 6
• 230000003612 virological effect Effects 0.000 description 6
• 238000005406 washing Methods 0.000 description 6
• 238000001262 western blot Methods 0.000 description 6
• 241000238631 Hexapoda Species 0.000 description 5
• 102100034343 Integrase Human genes 0.000 description 5
• 208000008839 Kidney Neoplasms Diseases 0.000 description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 description 5
• 201000004681 Psoriasis Diseases 0.000 description 5
• 108020004511 Recombinant DNA Proteins 0.000 description 5
• 241000283984 Rodentia Species 0.000 description 5
• 206010039491 Sarcoma Diseases 0.000 description 5
• 239000011543 agarose gel Substances 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 230000008827 biological function Effects 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 230000024245 cell differentiation Effects 0.000 description 5
• 230000010261 cell growth Effects 0.000 description 5
• 238000002405 diagnostic procedure Methods 0.000 description 5
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
• 230000003053 immunization Effects 0.000 description 5
• 230000001965 increasing effect Effects 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 150000002632 lipids Chemical class 0.000 description 5
• 238000011068 loading method Methods 0.000 description 5
• 229910052751 metal Inorganic materials 0.000 description 5
• 239000002184 metal Substances 0.000 description 5
• 210000003739 neck Anatomy 0.000 description 5
• 210000000496 pancreas Anatomy 0.000 description 5
• 230000006798 recombination Effects 0.000 description 5
• 238000005215 recombination Methods 0.000 description 5
• 230000003248 secreting effect Effects 0.000 description 5
• 210000000952 spleen Anatomy 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 4
• 208000030507 AIDS Diseases 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 201000009030 Carcinoma Diseases 0.000 description 4
• 208000024172 Cardiovascular disease Diseases 0.000 description 4
• 108020004635 Complementary DNA Proteins 0.000 description 4
• 238000001712 DNA sequencing Methods 0.000 description 4
• 238000009007 Diagnostic Kit Methods 0.000 description 4
• 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 235000010469 Glycine max Nutrition 0.000 description 4
• 208000037357 HIV infectious disease Diseases 0.000 description 4
• 239000004365 Protease Substances 0.000 description 4
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 239000008049 TAE buffer Substances 0.000 description 4
• HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 238000001042 affinity chromatography Methods 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 238000003491 array Methods 0.000 description 4
• 210000003719 b-lymphocyte Anatomy 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 238000001574 biopsy Methods 0.000 description 4
• 210000001185 bone marrow Anatomy 0.000 description 4
• 210000000481 breast Anatomy 0.000 description 4
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 4
• 230000002759 chromosomal effect Effects 0.000 description 4
• 210000000349 chromosome Anatomy 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 210000001072 colon Anatomy 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 239000000975 dye Substances 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 210000003128 head Anatomy 0.000 description 4
• 208000014829 head and neck neoplasm Diseases 0.000 description 4
• 208000002672 hepatitis B Diseases 0.000 description 4
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 238000001114 immunoprecipitation Methods 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 208000000509 infertility Diseases 0.000 description 4
• 230000036512 infertility Effects 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 206010025135 lupus erythematosus Diseases 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 206010061311 nervous system neoplasm Diseases 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 238000004321 preservation Methods 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000008707 rearrangement Effects 0.000 description 4
• 238000010839 reverse transcription Methods 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 210000004739 secretory vesicle Anatomy 0.000 description 4
• 239000007790 solid phase Substances 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 238000001228 spectrum Methods 0.000 description 4
• 230000004936 stimulating effect Effects 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 241000701161 unidentified adenovirus Species 0.000 description 4
• 241000701447 unidentified baculovirus Species 0.000 description 4
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
• WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 208000003174 Brain Neoplasms Diseases 0.000 description 3
• 208000005623 Carcinogenesis Diseases 0.000 description 3
• 241000761389 Copa Species 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
• 208000012239 Developmental disease Diseases 0.000 description 3
• 102100029727 Enteropeptidase Human genes 0.000 description 3
• 108010013369 Enteropeptidase Proteins 0.000 description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
• 102000016359 Fibronectins Human genes 0.000 description 3
• 108010067306 Fibronectins Proteins 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 description 3
• 108060001084 Luciferase Proteins 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 208000014767 Myeloproliferative disease Diseases 0.000 description 3
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• 208000025966 Neurological disease Diseases 0.000 description 3
• 238000012408 PCR amplification Methods 0.000 description 3
• 208000002193 Pain Diseases 0.000 description 3
• 108090000284 Pepsin A Proteins 0.000 description 3
• 102000057297 Pepsin A Human genes 0.000 description 3
• 206010060862 Prostate cancer Diseases 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 229920005654 Sephadex Polymers 0.000 description 3
• 239000012507 Sephadex™ Substances 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 230000032683 aging Effects 0.000 description 3
• 208000037883 airway inflammation Diseases 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 229960000723 ampicillin Drugs 0.000 description 3
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 230000002424 anti-apoptotic effect Effects 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 229950004398 broxuridine Drugs 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 230000036952 cancer formation Effects 0.000 description 3
• 208000035269 cancer or benign tumor Diseases 0.000 description 3
• 150000001720 carbohydrates Chemical group 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 231100000504 carcinogenesis Toxicity 0.000 description 3
• 208000002458 carcinoid tumor Diseases 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 230000007850 degeneration Effects 0.000 description 3
• 229960000633 dextran sulfate Drugs 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 238000001962 electrophoresis Methods 0.000 description 3
• 210000002308 embryonic cell Anatomy 0.000 description 3
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 230000001605 fetal effect Effects 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 108060003552 hemocyanin Proteins 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 210000003917 human chromosome Anatomy 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 231100000535 infertility Toxicity 0.000 description 3
• 210000003292 kidney cell Anatomy 0.000 description 3
• 210000002751 lymph Anatomy 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 208000030159 metabolic disease Diseases 0.000 description 3
• 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 3
• 235000013336 milk Nutrition 0.000 description 3
• 239000008267 milk Substances 0.000 description 3
• 210000004080 milk Anatomy 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 210000004923 pancreatic tissue Anatomy 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 230000001323 posttranslational effect Effects 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 238000003753 real-time PCR Methods 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 238000010532 solid phase synthesis reaction Methods 0.000 description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 206010043554 thrombocytopenia Diseases 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 241001515965 unidentified phage Species 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• SMWADGDVGCZIGK-AXDSSHIGSA-N (2s)-5-phenylpyrrolidine-2-carboxylic acid Chemical compound N1[C@H](C(=O)O)CCC1C1=CC=CC=C1 SMWADGDVGCZIGK-AXDSSHIGSA-N 0.000 description 2
• LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
• 241001182632 Akko Species 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 206010002383 Angina Pectoris Diseases 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 241000972773 Aulopiformes Species 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• 108091033380 Coding strand Proteins 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 108010067770 Endopeptidase K Proteins 0.000 description 2
• 240000002989 Euphorbia neriifolia Species 0.000 description 2
• 108700024394 Exon Proteins 0.000 description 2
• 108060002716 Exonuclease Proteins 0.000 description 2
• 229920001917 Ficoll Polymers 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• 244000068988 Glycine max Species 0.000 description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 description 2
• 241000700721 Hepatitis B virus Species 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 102000003777 Interleukin-1 beta Human genes 0.000 description 2
• 108090000193 Interleukin-1 beta Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 206010027406 Mesothelioma Diseases 0.000 description 2
• 208000031888 Mycoses Diseases 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 208000030852 Parasitic disease Diseases 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 102000016611 Proteoglycans Human genes 0.000 description 2
• 108010067787 Proteoglycans Proteins 0.000 description 2
• 239000013614 RNA sample Substances 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 108700008625 Reporter Genes Proteins 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
• 102000002933 Thioredoxin Human genes 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000009843 Thyroglobulin Human genes 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• 241000700647 Variola virus Species 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000000996 additive effect Effects 0.000 description 2
• 239000000853 adhesive Substances 0.000 description 2
• 230000001070 adhesive effect Effects 0.000 description 2
• 231100000360 alopecia Toxicity 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 210000003651 basophil Anatomy 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 230000031018 biological processes and functions Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 230000006931 brain damage Effects 0.000 description 2
• 231100000874 brain damage Toxicity 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 238000010804 cDNA synthesis Methods 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 238000004140 cleaning Methods 0.000 description 2
• 239000013599 cloning vector Substances 0.000 description 2
• 210000003477 cochlea Anatomy 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 102000013165 exonuclease Human genes 0.000 description 2
• 210000003754 fetus Anatomy 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 150000004676 glycans Polymers 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 210000003714 granulocyte Anatomy 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000010166 immunofluorescence Methods 0.000 description 2
• 238000013198 immunometric assay Methods 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000008676 import Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 239000002054 inoculum Substances 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• 210000002510 keratinocyte Anatomy 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 201000002364 leukopenia Diseases 0.000 description 2
• 231100001022 leukopenia Toxicity 0.000 description 2
• 238000007834 ligase chain reaction Methods 0.000 description 2
• 201000005296 lung carcinoma Diseases 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 201000011682 nervous system cancer Diseases 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 229940055729 papain Drugs 0.000 description 2
• 235000019834 papain Nutrition 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000037452 priming Effects 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 208000023958 prostate neoplasm Diseases 0.000 description 2
• 235000021251 pulses Nutrition 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 238000006722 reduction reaction Methods 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 235000019515 salmon Nutrition 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 229960001967 tacrolimus Drugs 0.000 description 2
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
• 238000011285 therapeutic regimen Methods 0.000 description 2
• 108060008226 thioredoxin Proteins 0.000 description 2
• 229940094937 thioredoxin Drugs 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 229960002175 thyroglobulin Drugs 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
• 229940038773 trisodium citrate Drugs 0.000 description 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 238000002255 vaccination Methods 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
• WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 244000153158 Ammi visnaga Species 0.000 description 1
• 235000010585 Ammi visnaga Nutrition 0.000 description 1
• 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
• 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
• 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
• 208000037914 B-cell disorder Diseases 0.000 description 1
• 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102100021257 Beta-secretase 1 Human genes 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
• 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 239000005496 Chlorsulfuron Substances 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
• 206010009346 Clonus Diseases 0.000 description 1
• 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
• 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
• 108700010070 Codon Usage Proteins 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 238000011537 Coomassie blue staining Methods 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• DZLNHFMRPBPULJ-GSVOUGTGSA-N D-thioproline Chemical compound OC(=O)[C@H]1CSCN1 DZLNHFMRPBPULJ-GSVOUGTGSA-N 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• 102000003915 DNA Topoisomerases Human genes 0.000 description 1
• 108090000323 DNA Topoisomerases Proteins 0.000 description 1
• 108010025600 DNA polymerase iota Proteins 0.000 description 1
• 102100035472 DNA polymerase iota Human genes 0.000 description 1
• 230000007023 DNA restriction-modification system Effects 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 241000283715 Damaliscus lunatus Species 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 108010055325 EphB3 Receptor Proteins 0.000 description 1
• 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 1
• 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 1
• 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 244000182067 Fraxinus ornus Species 0.000 description 1
• 235000002917 Fraxinus ornus Nutrition 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000002068 Glycopeptides Human genes 0.000 description 1
• 108010015899 Glycopeptides Proteins 0.000 description 1
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
• 241000219146 Gossypium Species 0.000 description 1
• 241000825469 Haemulon vittatum Species 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 206010019695 Hepatic neoplasm Diseases 0.000 description 1
• 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
• 101000740689 Homo sapiens C4b-binding protein beta chain Proteins 0.000 description 1
• 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 1
• 101001090813 Homo sapiens Proteasome subunit alpha type-6 Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 101710203526 Integrase Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 241000665848 Isca Species 0.000 description 1
• 241000274177 Juniperus sabina Species 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 241000948268 Meda Species 0.000 description 1
• 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 108091092724 Noncoding DNA Proteins 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 206010033647 Pancreatitis acute Diseases 0.000 description 1
• 206010033649 Pancreatitis chronic Diseases 0.000 description 1
• 241000282373 Panthera pardus Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 108020004518 RNA Probes Proteins 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 239000003391 RNA probe Substances 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 241001068295 Replication defective viruses Species 0.000 description 1
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
• 240000000111 Saccharum officinarum Species 0.000 description 1
• 235000007201 Saccharum officinarum Nutrition 0.000 description 1
• 241000181331 Saron Species 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010040844 Skin exfoliation Diseases 0.000 description 1
• 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 235000021536 Sugar beet Nutrition 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 241000723873 Tobacco mosaic virus Species 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 239000007984 Tris EDTA buffer Substances 0.000 description 1
• 101710162629 Trypsin inhibitor Proteins 0.000 description 1
• 229940122618 Trypsin inhibitor Drugs 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 208000006593 Urologic Neoplasms Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 101100379633 Xenopus laevis arg2-a gene Proteins 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 201000003229 acute pancreatitis Diseases 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 230000009824 affinity maturation Effects 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 230000004931 aggregating effect Effects 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
• 230000007720 allelic exclusion Effects 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 208000036878 aneuploidy Diseases 0.000 description 1
• 231100001075 aneuploidy Toxicity 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000009949 anti-apoptotic pathway Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000007503 antigenic stimulation Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 101150088826 arg1 gene Proteins 0.000 description 1
• 230000010516 arginylation Effects 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 238000013528 artificial neural network Methods 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 238000003766 bioinformatics method Methods 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 238000005460 biophysical method Methods 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• 201000002143 bronchus adenoma Diseases 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 235000013877 carbamide Nutrition 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 229950001357 celmoleukin Drugs 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 108700010039 chimeric receptor Proteins 0.000 description 1
• VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
• 230000014107 chromosome localization Effects 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000011281 clinical therapy Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 238000012136 culture method Methods 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000017858 demethylation Effects 0.000 description 1
• 238000010520 demethylation reaction Methods 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000035618 desquamation Effects 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• 239000012470 diluted sample Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 238000007878 drug screening assay Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• UXOLDCOJRAMLTQ-UHFFFAOYSA-N ethyl 2-chloro-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(Cl)=NO UXOLDCOJRAMLTQ-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000004744 fabric Substances 0.000 description 1
• 210000002458 fetal heart Anatomy 0.000 description 1
• 238000005111 flow chemistry technique Methods 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 230000006251 gamma-carboxylation Effects 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 125000003712 glycosamine group Chemical group 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 101150118163 h gene Proteins 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 230000002363 herbicidal effect Effects 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 102000051411 human PSMA6 Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 229960001438 immunostimulant agent Drugs 0.000 description 1
• 239000003022 immunostimulating agent Substances 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 230000016507 interphase Effects 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000026045 iodination Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 235000021374 legumes Nutrition 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 230000007498 myristoylation Effects 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229940127073 nucleoside analogue Drugs 0.000 description 1
• 230000005257 nucleotidylation Effects 0.000 description 1
• 230000031787 nutrient reservoir activity Effects 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 239000000123 paper Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000035778 pathophysiological process Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 229940080469 phosphocellulose Drugs 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 150000003058 platinum compounds Chemical group 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 210000004224 pleura Anatomy 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Polymers 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 230000013823 prenylation Effects 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 230000009219 proapoptotic pathway Effects 0.000 description 1
• 108010077112 prolyl-proline Proteins 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000030788 protein refolding Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000011897 real-time detection Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 208000025644 recurrent pneumonia Diseases 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000009703 regulation of cell differentiation Effects 0.000 description 1
• 230000021014 regulation of cell growth Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000012827 research and development Methods 0.000 description 1
• 201000004846 retroperitoneal sarcoma Diseases 0.000 description 1
• 208000009146 rhinoscleroma Diseases 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 102220055516 rs76646066 Human genes 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• 238000007790 scraping Methods 0.000 description 1
• 238000012106 screening analysis Methods 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 239000012192 staining solution Substances 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 238000006277 sulfonation reaction Methods 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 238000010798 ubiquitination Methods 0.000 description 1
• 230000034512 ubiquitination Effects 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1